Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aldeyra TherapeuticsALDX +4.28%29 Equity-to-Asset is 0.63 as of Mar. 2026, which is 25% below its 10-year median of 0.84. GuruFocus rates ALDX with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,414 Biotechnology companies, Aldeyra Therapeutics ranks worse than 55.8% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Aldeyra Therapeutics Equity-to-Asset Related Terms
Aldeyra Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Aldeyra Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALDX vs NTHI, BMEA, PTHS: Equity-to-Asset Comparison
For the Biotechnology subindustry, Aldeyra Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aldeyra Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Aldeyra Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Aldeyra Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aldeyra Therapeutics (ALDX) has a Equity-to-Asset of 0.63 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aldeyra Therapeutics and its competitors. This is 25% below median its historical median of 0.84. Over the past decade, Aldeyra Therapeutics' Equity-to-Asset has ranged from 0.61 to 0.93. According to the industry distribution chart, Aldeyra Therapeutics ranks #789 out of 1414 companies in the Biotechnology industry, placing it in the top 55.8%.
Is Aldeyra Therapeutics' Equity-to-Asset too high?
Aldeyra Therapeutics' current Equity-to-Asset of 0.63 is 25% below median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 0.93. The Biotechnology industry median Equity-to-Asset is 0.68. Aldeyra Therapeutics' value of 0.63 is 7.4% below this industry median. Based on the distribution chart, Aldeyra Therapeutics ranks #789 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aldeyra Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' Equity-to-Asset compare to NTHI and BMEA?
According to the Biotechnology industry distribution chart, Aldeyra Therapeutics ranks #789 out of 1414 companies for Equity-to-Asset. This places Aldeyra Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Aldeyra Therapeutics' value of 0.63 is 7.4% below this benchmark. Historically, Aldeyra Therapeutics' own Equity-to-Asset has ranged from 0.61 to 0.93 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 0.68, Aldeyra Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aldeyra Therapeutics's current Equity-to-Asset of 0.63 is 7.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aldeyra Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aldeyra Therapeutics's current Equity-to-Asset is 0.63, which is 25% below median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (ALDX) has a current Equity-to-Asset of 0.63. The current Equity-to-Asset is 0.63, which is 25% below median its 10-year median of 0.84 and 7.4% below the Biotechnology industry median of 0.68. Aldeyra Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Aldeyra Therapeutics (ALDX), the current Equity-to-Asset is 0.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
29GF Score
Get the complete analysis for ALDX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALDX has been successfully added to your 
